Samlyn Capital LLC Purchases 3,774,658 Shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)

Samlyn Capital LLC grew its position in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) by 160.7% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,123,021 shares of the company’s stock after purchasing an additional 3,774,658 shares during the quarter. Samlyn Capital LLC owned approximately 9.79% of Corvus Pharmaceuticals worth $11,144,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Separately, Towerview LLC lifted its holdings in shares of Corvus Pharmaceuticals by 4.6% in the second quarter. Towerview LLC now owns 400,000 shares of the company’s stock worth $728,000 after buying an additional 17,500 shares in the last quarter. Institutional investors and hedge funds own 46.64% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on CRVS shares. StockNews.com raised shares of Corvus Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, September 13th. LADENBURG THALM/SH SH boosted their target price on shares of Corvus Pharmaceuticals from $12.00 to $21.00 and gave the stock a “buy” rating in a report on Monday, September 16th. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $10.83.

Corvus Pharmaceuticals Stock Down 8.0 %

Corvus Pharmaceuticals stock opened at $5.44 on Tuesday. The company has a market cap of $340.28 million, a price-to-earnings ratio of -10.46 and a beta of 1.13. The firm’s fifty day moving average is $3.79 and its 200 day moving average is $2.55. Corvus Pharmaceuticals, Inc. has a 52-week low of $1.05 and a 52-week high of $6.15.

Corvus Pharmaceuticals (NASDAQ:CRVS) last released its quarterly earnings results on Tuesday, August 6th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.05. During the same quarter in the previous year, the company posted ($0.14) EPS. On average, equities research analysts anticipate that Corvus Pharmaceuticals, Inc. will post -0.45 earnings per share for the current fiscal year.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.